Litcius/Paper detail

18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial

Ashesh B. Jani, Eduard Schreibmann, Subir Goyal, Raghuveer Halkar, Bruce Hershatter, Peter J. Rossi, Joseph W. Shelton, Pretesh Patel, Karen M. Xu, Mark M. Goodman, Viraj A. Master, Shreyas Joshi, Ömer Küçük, Bradley Curtis Carthon, Mehmet Asım Bilen, Olayinka A. Abiodun-Ojo, Akinyemi A. Akintayo, Vishal R. Dhere, David M. Schuster

2021The Lancet183 citationsDOIOpen Access PDF

Topics & Concepts

MedicineProstatectomyProstate cancerRadiation therapyAndrogen deprivation therapyClinical endpointSalvage therapyRandomized controlled trialAdverse effectNuclear medicineCancerSurgeryRadiologyInternal medicineChemotherapyProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentMedical Imaging Techniques and Applications
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial | Litcius